subject area of
- Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α Journal Articles
- Miglustat as a therapeutic agent: prospects and caveats Journal Articles
- Murine β-galactosidase stability is not dependent on temperature or protective protein/cathepsin A Journal Articles
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial Journal Articles
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. Journal Articles